AMGEN Inc
NASDAQ: AMGN
$280.01
-$13.99 (-4.8%)
Closing Price on November 26, 2024
AMGN Articles
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
If you have been a reader of 24/7 Wall St. for long, you know that we appreciate companies that pay dividends just about as much the investors who buy companies because of their great dividends. ...
Published:
Last Updated:
Earnings season is in full throttle and many major companies are due to report in the week ahead. Some of the key reports we are featuring for detailed earnings previews are the following: Baidu,...
Published:
Last Updated:
Active traders and day traders have many stocks to choose from this Monday morning. We are tracking news and moves in shares of Amgen, Inc. (NASDAQ: AMGN), Level 3 Communications (NASDAQ:...
Published:
Last Updated:
We have already seen (some) of the position changes of Warren Buffett, but the old guy wouldn’t share many ‘confidential positions’ so we are whale watching in other ponds. We wanted to take...
Published:
Next week may be short because of a holiday, but it is going to be a very busy week for earnings. We have tried to narrow the field down to the very top earnings and given previews on each. There...
Published:
Last Updated:
Biotech is becoming the ever-shrinking stock sector. It is almost weekly now that a new biotech acquisition is announced. Big Pharma in the United States and large drugmakers internationally...
Published:
Last Updated:
It is time for “The Daily Dividend” and we have an interesting call ahead. How long has it been that Amgen Inc. (NASDAQ: AMGN) has been touted as a “Should Be” dividend stock? Too...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Thursday morning. Amazon.com Inc. (NASDAQ: AMZN) Raised to Outperform at William...
Published:
Last Updated:
Investors love huge biotech opportunities for growth. Investors also love to get paid in the form of dividends. Unfortunately, the terms “dividend” and “biotech” never match up. While...
Published:
Last Updated:
Despite big companies holding unprecedented billions and billions of dollars on their balance sheets, it is shocking how many companies do not reward shareholders in the most classic sense by paying...
Published:
Last Updated:
Earnings season is in full swing and we have a back-breaker of an earnings week ahead of us. There are some 11 DJIA components reporting earnings and a whole slew of other major market-movers and...
Published:
Last Updated:
After about two weeks of being quiet and dark, Wall Street research departments are back after the holidays. These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations...
Published:
Last Updated:
2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer ten-baggers with...
Published:
Last Updated:
These are some of this Wednesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. ABB Ltd. (NYSE: ABB) Raised to Buy at Stern Agee. Akamai Technologies Inc....
Published:
Last Updated: